Search

Your search keyword '"Catriona H.M. Jamieson"' showing total 21 results
Start Over Author "Catriona H.M. Jamieson"
21 results on '"Catriona H.M. Jamieson"'

1. Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer

Author

Takeshi Hirata, Seung Chol Park, Michelle T. Muldong, Christina N. Wu, Tomonori Yamaguchi, Amy Strasner, Omer Raheem, Hiromi Kumon, Robert L. Sah, Nicholas A. Cacalano, Catriona H.M. Jamieson, Christopher J. Kane, Koichi Masuda, Anna A. Kulidjian, and Christina A.M. Jamieson

Subjects
Diseases of the genitourinary system. Urology, RC870-923
Abstract

Objective: Bone metastasis occurs in up to 90% of men with advanced prostate cancer and leads to fractures, severe pain and therapy-resistance. Bone metastases induce a spectrum of types of bone lesions which can respond differently to therapy even within individual prostate cancer patients. Thus, the special environment of the bone makes the disease more complicated and incurable. A model in which bone lesions are reproducibly induced that mirrors the complexity seen in patients would be invaluable for pre-clinical testing of novel treatments. The microstructural changes in the femurs of mice implanted with PCSD1, a new patient-derived xenograft from a surgical prostate cancer bone metastasis specimen, were determined. Methods: Quantitative micro-computed tomography (micro-CT) and histological analyses were performed to evaluate the effects of direct injection of PCSD1 cells or media alone (Control) into the right femurs of Rag2−/−γc−/− male mice. Results: Bone lesions formed only in femurs of mice injected with PCSD1 cells. Bone volume (BV) was significantly decreased at the proximal and distal ends of the femurs (p

Published
2016
Full Text
View/download PDF

2. Telomerase-Targeted Therapies in Myeloid Malignancies

Author

Julian A. Waksal, Claudia Bruedigam, Rami S. Komrokji, Catriona H.M. Jamieson, and John O. Mascarenhas

Subjects
Hematology
Abstract

Human telomeres are tandem arrays that are predominantly composed of 5'-TTAGGG-3' nucleotide sequences at the terminal ends of chromosomes. These sequences serve two primary functions; they persevere genomic integrity by protecting the ends of chromosomes preventing inappropriate degradation by DNA repair mechanisms, and they prevent loss of genetic information during cellular division. When telomeres shorten to reach a critical length, termed the Hayflick limit, cell senescence or death is triggered. Telomerase is a key enzyme involved in synthesizing and maintaining the length of telomeres within rapidly dividing cells and is up regulated across nearly all malignant cells. Accordingly, targeting telomerase to inhibit uncontrolled cell growth has been an area of great interest for decades. In this review, we summarize telomere and telomerase biology as it relates to both physiologic and malignant cells. We go on to discuss the development of telomere and telomerase targeted therapeutic candidates within the realm of myeloid malignancies. We overview all mechanisms of targeting telomerase that are currently in development with a particular focus on imetelstat, an oligonucleotide with direct telomerase inhibitory properties that has advanced the furthest in clinical development and has demonstrated promising data in multiple myeloid malignancies.

Published
2023

3. Supplementary Table 8 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

XLSX file - 24K, PCR Primer sequences.

Published
2023

4. Supplementary Figure 9 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

PDF file - 113K, Bcl2 protein expression in wild-type and Tyk2 knockout mice.

Published
2023

5. Supplementary Figure 4 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

PDF file - 74K, Knockdown efficiency and BCL2 expression in JURKAT cells.

Published
2023

6. Supplementary Table 2 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

XLSX file - 525K, Summary of inducible shRNA screen on three T-ALL cell lines.

Published
2023

7. Supplementary Figure Legend and Methods from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

PDF file - 138K

Published
2023

8. Supplementary Figure 6 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

PDF file - 32K, Expressions of IL-10 and IL-10 receptors, and effect of an anti-IL10 neutralizing antibody on growth of T-ALL cell lines.

Published
2023

9. Supplementary Table 3 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

XLSX file - 30K, Targeting sequences for shRNAs.

Published
2023

10. Supplementary Figure 2 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

PDF file - 68K, Cell cycle distribution after TYK2 knockdown in T-ALL cells.

Published
2023

11. Supplementary Table 5 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

XLSX file - 14291K, TYK2 genotype in 17 T-ALL cell lines.

Published
2023

12. Supplementary Table 4 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

XLSX file - 35K, Sensitivities to TYK2 knockdown and JAK Inhibitor I treatment, and phosphorylation status of downstream signaling molecules in T-ALL cell lines and Ba/F3 clones.

Published
2023

13. Supplementary Figure 1 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

PDF file - 61K, Validation of shRNA constructs.

Published
2023

14. Supplementary Table 1 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

XLSX file - 36K, Cell viability profile by RAPID assay.

Published
2023

15. Supplementary Figure 5 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

PDF file - 273K, Confirmation of CD3 expression on OP9 DL1 outgrowth cells.

Published
2023

16. Supplementary Figure 7 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

PDF file - 24K, Effect of JAK kinase inhibitors with varying TYK2-specificity on growth and viability of T-ALL cells.

Published
2023

17. Supplementary Table 6 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

XLSX file - 23K, Clinical, biologic and molecular characteristics of the T-ALL patient samples analyzed. See separate file.

Published
2023

18. Supplementary Figure 8 from TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Author

A. Thomas Look, Brian J. Druker, Louis M. Staudt, Andrew P. Weng, Catriona H.M. Jamieson, Nathanael S. Gray, Mathias Müller, Richard Moriggl, Ross L. Levine, Donna S. Neuberg, Michelle A. Kelliher, Jessica Tatarek, Yebin Ahn, Maria Kleppe, Yandan Yang, Wenjun Zhou, Angela G. Fleischman, Wenxue Ma, Arla Yost, Bill H. Chang, Jason Glover, Vu N. Ngo, Alejandro Gutierrez, Jeffrey W. Tyner, and Takaomi Sanda

Abstract

PDF file - 105K, Signaling and cell cycle distribution after JAK inhibitor I treatment.

Published
2023

19. Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells

Author

Inge van der Werf, Phoebe K. Mondala, S. Kathleen Steel, Larisa Balaian, Luisa Ladel, Cayla N. Mason, Raymond H. Diep, Jessica Pham, Jacqueline Cloos, Gertjan J.L. Kaspers, Warren C. Chan, Adam Mark, James J. La Clair, Peggy Wentworth, Kathleen M. Fisch, Leslie A. Crews, Thomas C. Whisenant, Michael D. Burkart, Mary E. Donohoe, Catriona H.M. Jamieson, Hematology laboratory, AII - Cancer immunology, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Pediatrics, and CCA - Cancer Treatment and quality of life

Subjects
Adult, Myeloid, Pediatric Cancer, RNA Splicing, Acute, Regenerative Medicine, General Biochemistry, Genetics and Molecular Biology, Rare Diseases, Stem Cell Research - Nonembryonic - Human, Genetics, Humans, Protein Isoforms, RBFOX2, Child, CD47, pediatric AML, Cancer, Pediatric, Leukemia, Stem Cells, SF3B1, Human Genome, Hematology, embryonic stem cells, Stem Cell Research, hematopoietic stem cells, Repressor Proteins, Mutation, pre-mRNA splicing, Stem Cell Research - Nonembryonic - Non-Human, RNA Splicing Factors, splicing modulation
Abstract

Pediatric acute myeloid leukemia (pAML) is typified by high relapse rates and a relative paucity of somatic DNA mutations. Although seminal studies show that splicing factor mutations and mis-splicing fuel therapy-resistant leukemia stem cell (LSC) generation in adults, splicing deregulation has not been extensively studied in pAML. Herein, we describe single-cell proteogenomics analyses, transcriptome-wide analyses of FACS-purified hematopoietic stem and progenitor cells followed by differential splicing analyses, dual-fluorescence lentiviral splicing reporter assays, and the potential of a selective splicing modulator, Rebecsinib, in pAML. Using these methods, we discover transcriptomic splicing deregulation typified by differential exon usage. In addition, we discover downregulation of splicing regulator RBFOX2 and CD47 splice isoform upregulation. Importantly, splicing deregulation in pAML induces a therapeutic vulnerability to Rebecsinib in survival, self-renewal, and lentiviral splicing reporter assays. Taken together, the detection and targeting of splicing deregulation represent a potentially clinically tractable strategy for pAML therapy.

Published
2023

20. Reversal of malignant ADAR1 splice isoform switching with Rebecsinib

Author

Leslie A. Crews, Wenxue Ma, Luisa Ladel, Jessica Pham, Larisa Balaian, S. Kathleen Steel, Phoebe K. Mondala, Raymond H. Diep, Christina N. Wu, Cayla N. Mason, Inge van der Werf, Isabelle Oliver, Eduardo Reynoso, Gabriel Pineda, Thomas C. Whisenant, Peggy Wentworth, James J. La Clair, Qingfei Jiang, Michael D. Burkart, and Catriona H.M. Jamieson

Subjects
Genetics, Molecular Medicine, Cell Biology
Published
2023

21. A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition

Author

Catriona Jamieson, Maurizio Pellecchia, Wenxue Ma, Lawrence S.B. Goldstein, Alice Y. Shih, Maryla Krajewska, Kelly A. Frazer, Janine M. Low-Marchelli, Anil Sadarangani, John C. Reed, Karen Messer, Ifat Geron, Minya Pu, Christian L. Barrett, Dayong Zhai, Sheldon R. Morris, Lei Bao, Daniel Goff, Hye Jung E. Chun, Jessica M. Rusert, Thomas J. Hudson, Angela Court Recart, Kim Hien T. Dao, Peggy Wentworth, Mark D. Minden, Ryan Chuang, Christina Jamieson, Jason Gotlib, Kristen M. Smith, Jun Wei, Kamran Shazand, Giovanni Martinelli, Heather Leu, Marco A. Marra, Larisa Balaian, Daniel J. Goff, Angela Court Recart, Anil Sadarangani, Hye-Jung Chun, Christian L. Barrett, Maryla Krajewska, Heather Leu, Janine Low-Marchelli, Wenxue Ma, Alice Y. Shih, Jun Wei, Dayong Zhai, Ifat Geron, Minya Pu, Lei Bao, Ryan Chuang, Larisa Balaian, Jason Gotlib, Mark Minden, Giovanni Martinelli, Jessica Rusert, Kim-Hien Dao, Kamran Shazand, Peggy Wentworth, Kristen M. Smith, Christina A.M. Jamieson, Sheldon R. Morri, Karen Messer, Lawrence S.B. Goldstein, Thomas J. Hudson, Marco Marra, Kelly A. Frazer, Maurizio Pellecchia, John C. Reed, and Catriona H.M. Jamieson

Subjects
Stromal cell, Myeloid, Biology, Article, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, medicine, Genetics, Humans, Progenitor cell, Protein Kinase Inhibitors, 030304 developmental biology, 0303 health sciences, Leukemia, Leukemia stem cells (LSCs), Myeloid leukemia, Cell Biology, medicine.disease, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Proto-Oncogene Proteins c-bcl-2, 030220 oncology & carcinogenesis, Neoplastic Stem Cells, Cancer research, Molecular Medicine, sense organs, Bone marrow, Stem cell, Tyrosine kinase
Abstract

SummaryLeukemia stem cells (LSCs) play a pivotal role in the resistance of chronic myeloid leukemia (CML) to tyrosine kinase inhibitors (TKIs) and its progression to blast crisis (BC), in part, through the alternative splicing of self-renewal and survival genes. To elucidate splice-isoform regulators of human BC LSC maintenance, we performed whole-transcriptome RNA sequencing, splice-isoform-specific quantitative RT-PCR (qRT-PCR), nanoproteomics, stromal coculture, and BC LSC xenotransplantation analyses. Cumulatively, these studies show that the alternative splicing of multiple prosurvival BCL2 family genes promotes malignant transformation of myeloid progenitors into BC LSCS that are quiescent in the marrow niche and that contribute to therapeutic resistance. Notably, sabutoclax, a pan-BCL2 inhibitor, renders marrow-niche-resident BC LSCs sensitive to TKIs at doses that spare normal progenitors. These findings underscore the importance of alternative BCL2 family splice-isoform expression in BC LSC maintenance and suggest that the combinatorial inhibition of prosurvival BCL2 family proteins and BCR-ABL may eliminate dormant LSCs and obviate resistance.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results